普通外文研报
Medley (4480): FY12/26 beat likely to be confirmed at 2Q results
研报英文原文证据摘录
Medley (4480): FY12/26 beat likely to be confirmed at 2Q results
APR - Healthcare Coverage Cluster
Investment rating Company BofA Ticker Bloomberg symbol Analyst
Sumitomo Pharma DNPUF 4506 JP Koichi Mamegano
Topchoice Medical XZDXF 600763 CH Ethan Cui
WuXi Biologics WXIBF 2269 HK David Li
Zai Lab ZLAB ZLAB US David Li
Zai Lab XCDZF 9688 HK David Li
Zydus Lifesciences XMQLF ZYDUSLIF IN Neha Manpuria
UNDERPERFORM
Ain Holdings AINPF 9627 JP Ritsuo Watanabe
Autobio Diagnostics Co Ltd XQDXF 603658 CH Sandra Sun
Baiyunshan XOUFF 600332 CH Sandra Sun
Beijing Wantai Biological Pharmacy XBHIF 603392 CH David Li
CSPC Pharmaceutical CHJTF 1093 HK Ethan Cui
EBOS Group Limited EBOSF EBO NZ Lyanne Harrison
EBOS Group Limited XEBOF EBO AU Lyanne Harrison
Eisai ESALF 4523 JP Koichi Mamegano
Frontage FGHQF 1521 HK David Li
Healius Limited PHCRF HLS AU Lyanne Harrison
Joinn Lab XQTSF 6127 HK David Li
Joinn Lab JOLCF 603127 CH David Li
Kyowa Kirin KYKOF 4151 JP Koichi Mamegano
Lupin XEFSF LPC IN Neha Manpuria
Mankind Pharma XDXZF MANKIND IN Neha Manpuria
Medipal Holdings MEPDF 7459 JP Ritsuo Watanabe
Olympus Corp. OCPNF 7733 JP Ritsuo Watanabe
Ovctek XOCKF 300595 CH David Li
Pharmaron XLYGF 300759 CH David Li
Pien Tze Huang XUVHF 600436 CH Sandra Sun
Shanghai Pharmaceuticals XKCRF 601607 CH David Li
SMS SMSZF 2175 JP Ritsuo Watanabe
Sun Pharma XPUCF SUNP IN Neha Manpuria
TigerMed XHTHF 300347 CH David Li
Yifeng Pharmacy XYHCF 603939 CH Ethan Cui
Zhifei XCHOF 300122 CH David Li
iQmethod SM Measures Definitions
Business Performance Numerator Denominator
Return On Capital Employed NOPAT = (EBIT + Interest Income) × (1 − Tax Rate) + Goodwill Amortization Total Assets − Current Liabilities + ST Debt + Accumulated Goodwill
Amortization
Return On Equity Net Income Shareholders’ Equity
本摘录由系统从所标注的 PDF 证据页直接提取并保留英文原文,不做批量翻译;登录后在阅读器切换中文时才按需翻译。
打开研报阅读器